Subscribe

NanoRepro AG (NN6.DE)

EUR2.29 +0.17 (+8.02%)
DE XETRA Healthcare Medical - Diagnostics & Research
Address Untergasse 8 35037
Marburg, DE
CEO Lisa Jungst
Website nanorepro.com
IPO 2009-10-22
ISIN DE0006577109

Explore sections of this company profile

Also trades on Deutsche Börse · NN6.DE (EUR) Other OTC · NNGRF (USD)
Description

Based in Marburg, Germany, NanoRepro AG specializes in the development, manufacturing, and international distribution of both swift diagnostic tests and nutritional supplements, serving individual consumers and healthcare professionals alike. Their diagnostic offerings encompass family planning, various disease detection, identification of food intolerances, allergies, and infectious diseases. This portfolio includes dedicated rapid test lines for allergies, family planning, and preventive healthcare. For hospitals and medical practices, they provide point-of-care tests capable of detecting conditions such as HIV, human cardiac Troponin I, D-dimer, streptococci antigens, influenza types A and B, and microalbumin. The company also produces immunochromatographic lateral flow tests for biomarker identification, alongside rapid SARS-CoV-2 antibody and antigen tests. Complementing their diagnostics, NanoRepro AG offers food supplements tailored for men and women, distributed via online stores and pharmacies.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR2.29 +0.17 (+8.02%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
13.7K
Beta
0.53
Float Shares
12.95M
Free Float %
102.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+2.81% +8.93% +20.39% +18.06% +21.19% +18.83% +34.56% -21.12% -70.77% +83.63% -53.90%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
2.29
DCF (Levered) 1.33 -41.7%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 2 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
18.90
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Diagnostics & Research: +7.9%
    +46.0% ★ Q2'25: +74.3% (vs Q2'23)
  • ✗
    EPS growth Medical - Diagnostics & Research: +30.8%
    +56.8% ★ Q2'25: +68.1% (vs Q2'23)
  • ✓
    FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%
    +200.6% Q2'25: +83.5% (vs Q2'23)
  • ✗
    EBIT margin Medical - Diagnostics & Research: +9.6%
    -74.2% Q2'25: -34.8% (vs Q2'23)
  • ✗
    ROIC Medical - Diagnostics & Research: +5.2%
    -11.9% Q2'25: -11.2% (vs Q2'23)
  • ✓
    Share dilution Medical - Diagnostics & Research: 0.0%
    -0.8% ★ Q2'25: -2.3% (vs Q2'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×
    0.00× Q2'25: 0.00× (vs Q2'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.42) × ERP
WACC = 100% × Ke + 0% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 2.29
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
2 Rev. Ana.
2 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
16.93M
est: 1.40M (+1,109.2%)
162.72M
est: 1.87M (+8,578.9%)
38.49M
est: 3.06M (+1,158.2%)
3.18M
est: 4.83M (-34.1%)
4.65M
est: 5.17M (-10.0%)
15.37M
est.
18.05M
17.60M – 18.49M
+17.4% YoY
21.10M
20.58M – 21.62M
+16.9% YoY
24.70M
24.09M – 25.31M
+17.1% YoY
EBITDA
4.67M
est: -373.7K (+1,348.7%)
38.82M
est: -500.5K (+7,856.3%)
-4.35M
est: -816.6K (-433.3%)
-4.66M
est: -1.29M (-261.5%)
-3.42M
est: -1.38M (-148.0%)
-4.10M
est.
-4.82M
-4.94M – -4.70M
-17.4% YoY
-5.63M
-5.77M – -5.49M
-16.9% YoY
-6.59M
-6.76M – -6.43M
-17.1% YoY
EBIT
2.80M
est: -406.5K (+788.5%)
38.81M
est: -544.4K (+7,228.3%)
-4.36M
est: -888.3K (-391.2%)
-4.68M
est: -1.40M (-233.8%)
-3.45M
est: -1.50M (-130.0%)
-4.46M
est.
-5.24M
-5.37M – -5.11M
-17.4% YoY
-6.13M
-6.28M – -5.98M
-16.9% YoY
-7.17M
-7.35M – -7.00M
-17.1% YoY
Net Income
1.69M
est: -2.06M (+182.4%)
29.72M
est: -1.45M (+2,146.7%)
-3.72M
est: -363.1K (-925.8%)
-4.69M
est: 1.09M (-530.2%)
-2.05M
est: -1.72M (-18.7%)
-2.09M
est.
-504.5K
-520.7K – -488.4K
+75.9% YoY
500.0K
488.4K – 520.7K
+199.1% YoY
1.51M
1.47M – 1.56M
+202.7% YoY
SGA
1.85M
est: 491.5K (+276.0%)
14.29M
est: 658.3K (+2,070.6%)
4.96M
est: 1.07M (+362.0%)
1.36M
est: 1.70M (-19.7%)
4.66M
est: 1.81M (+156.7%)
5.39M
est.
6.34M
6.18M – 6.49M
+17.4% YoY
7.41M
7.23M – 7.59M
+16.9% YoY
8.67M
8.46M – 8.89M
+17.1% YoY
EPS
0.18
est: -0.16 (+210.4%)
2.30
est: -0.12 (+2,097.6%)
-0.29
est: -0.03 (-907.5%)
-0.37
est: 0.09 (-528.5%)
-0.16
est: -0.14 (-17.1%)
-0.17
est.
-0.04
-0.04 – -0.04
+75.8% YoY
0.04
0.04 – 0.04
+200.0% YoY
0.12
0.12 – 0.12
+200.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-28 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-27 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-26 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-25 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-22 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-21 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-20 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-19 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-18 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-15 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-14 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-13 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-12 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-11 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-08 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-07 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-06 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-05 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-05-04 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-04-30 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-04-29 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-04-28 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-04-27 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-04-24 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-04-23 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-04-22 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-04-21 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-04-20 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-04-17 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5
2026-04-16 C+ 2/5 4/5 1/5 1/5 1/5 1/5 5/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
2.23M
OE per share TTM
0.17
Owner's Yield
9.67%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
0.2%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-156.8K
Shares Outstanding
12.61M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Lisa Jungst President of the Management Board & Chief Executive Officer — female
Stefan Pieh Chief Financial Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Diagnostics & Research